objeCtives: To evaluate the cost-effectiveness of several sequential treatment strategies for chronic myeloid leukemia (CML) dependent on early molecular response (EMR) in the Austrian healthcare context. Methods: We adapted a previously developed Markov state-transition model to incorporate different treatment options (imatinib, dasatinib, nilotinib) dependent on achievement of EMR after 3 months. We analyzed eight sequential treatment strategies using cohort simulation over a lifelong time horizon. Model parameters were extracted from published literature, epidemiological and economic databases. We applied a 3% discount for health outcomes and costs. We analyzed 3 different base-case scenarios for patients not achieving an EMR after 3-months of imatinib treatment that were switched to a second-generation TKI, assuming three different effectiveness for these second-generation TKIs. Comprehensive sensitivity analyses were conducted. Results: The base-case analysis resulted in two non-dominated strategies: (1) imatinib, followed by nilotinib in case of non-achieved EMR at 3 months and dasatinib after treatment failure or imatinib continuation in case of achieved 3-month EMR and nilotinib after treatment failure; (2) nilotinib followed by its continuation in case of nonachieved EMR at 3 months or switch to imatinib in case of achieved 3 month EMR and dasatinib after treatment failure. Depending on the scenario, strategy 2 resulted in an incremental cost-effectiveness ratio (ICER) of € 84,200/QALY, € 118,500/QALY or € 142,200/QALY gained compared to the baseline strategy. Remaining strategies were excluded due to dominance. Sensitivity analyses on generic pricing of imatinib showed that starting with a more potent second-generation TKI and switching to imatinib after an achieved EMR are the preferred strategies. ConClusions: Based on our analyses, we suggest nilotinib and its continuation for non-achieved EMR at 3 months or switch to imatinib after achieved 3-month EMR and dasatinib after treatment failure as a cost-effective strategy for Austria if the willingness-to pay threshold is at least around € 120,000/QALY.
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EstimAtiNG thE PuBliC hEAlth imPACt of A vACCiNAtioN ProGrAmmE With A NoNAvAlENt hPv vACCiNE iN GErmANy
Largeron N 1 , Petry K 2 , Jacob JA 3 , Bianic F 4 , Anger D 4 , Nikoglou T 1 1 SPMSD, Lyon, France, 2 Klinikum Wolfsburg, Wolfsburg, Germany, 3 MAPI Group, Uxbridge, UK, 4 Mapi Group, Nanterre, France objeCtives: The nonavalent vaccine, by protecting against five additional oncogenic HPV types, and nine HPV types in total (6, 11, 16, 18, 31, 33, 45, 52 and 58), is objeCtives: This study assessed, from a societal perspective, the cost-effectiveness of idelalisib in combination with rituximab versus rituximab monotherapy for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). CLL is the most common leukemia in the Western world and is clinically characterized by peripheral blood B-cell lymphocytosis as well as lymphadenopathy, organomegaly, cytopenias and systemic symptoms in advanced stages. Methods: The cost-effectiveness model adopted a lifetime horizon with three health states: 1) pre-progression; 2) post-progression and 3) death. Patients enter in the model in the pre-progression state and in each cycle (1 week length) may survive without progression; advance to post-progression or die. Remission was not considered in the model: patients in post-progression state remain there until death. Costs and benefits were estimated for the Portuguese setting, and discounted at 5%, as recommended by national guidelines. Univariate and probabilistic sensitivity analyses assessed the robustness of results. Clinical efficacy, safety and utility data were based on published evidence, while survival curves were extrapolated using a Weibull function. Costs estimation was based on Diagnosis Related Group database, national legislation and opinions of an experts' panel. Model outputs included life years gained, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Results: Survival gains as well as direct medical costs were higher with idelalisib in association with rituximab compared to rituximab monotherapy, but costs related to adverse events and end-of-life care were lower. The ICER was of 32.702€ /QALY and 15.935€ /LY. Results were sensitive to the discount rates with an undiscounted ICER of 21.942 € . For other parameters univariate analyses ranged between 31.228€ /QALY and 34.176 € /QALY. PSA resulted in a median willingness to pay of 34.801€ /QALYs or 17.000€ /LY. ConClusions: Idelalisib plus rituximab in the treatment of relapsed/refractory CLL, compared with rituximab plus placebo, is cost-effective in Portugal.
PCN181 loss of oPPortuNity liNKEd With thE suBoPtimAl CovErAGE rAtE of hPv vACCiNAtioN iN frANCE
Uhart M 1 , Dahlab A 1 , Bresse X 1 , Largeron N 2 1 Sanofi Pasteur MSD, Lyon, France, 2 SPMSD, Lyon, France objeCtives: HPV vaccination is recommended in France for girls aged 11 to 14 with a catch-up from 15 to 19 years old. Though, with a cumulative coverage rate (VCR) of less than 20% in girls aged 16 years old for the HPV vaccine, France has one of the lowest VCR in Europe. The objective of the present study is to estimate the burden that would be averted by reaching in France the VCR currently observed in several EU countries. Methods: A dynamic transmission model including a wide range of health and cost outcomes related to cervical, anal, vulvar, vaginal diseases and genital warts, was adapted to French setting. The health outcomes resulting from the vaccination of girls with quadrivalent HPV vaccine was assessed according to two different vaccine coverage rates: (i) the 2014 cumulative coverage rate in girls aged 16 years old of 17.2% (reported by the InVS in July 2014) (ii) a VCR of 70% as observed in several European countries. Results: The analyses demonstrated that reaching in France a VCR comparable to those observed in other European countries would lead to avert additional 3,873,070 genital warts, 582,339 CIN2/3, 78,899 cervical cancers, 1,253 vaginal cancers, 1,756 vulvar cancers, and 17,993 anal cancers (including 4,774 in males) over 100 years. Overall, 27,222 deaths from HPV cancers could be averted by increasing the VCR at 70%. ConClusions: The present study shows that the suboptimal HPV vaccination coverage rate observed in France is linked with a tremendous loss of opportunity for the French population. Even though the applied VCR is not representative of the VCR of the entire targeted population, it is clear that benefits of HPV vaccination are still undermined. In a context where cancer is a health priority in France, combined efforts to improve HPV vaccination coverage rate must be pursued.
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Cost-EffECtivENEss of CEritiNiB iN PrEviously trEAtEd PAtiENts With CrizotiNiB iN ANAPlAstiC lymPhomA KiNAsE-PositivE (AlK+) NoN-smAll CEll luNG CANCEr iN CANAdA
Zhou Z 1 , Hurry M 2 , Zhang J 3 , Fan L 4 , Zhang C 4 , Xie J 5 1 Analysis Group Inc., New York, NY, USA, 2 Novartis Pharmaceuticals Inc., Dorval, QC, Canada, 3 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4 Analysis Group, Inc., Boston, MA, USA, 5 Analysis Group Inc., Boston, MA, USA objeCtives: To assess the cost-effectiveness of ceritinib versus alternatives in patients who discontinue treatment with crizotinib in anaplastic lymphoma kinasepositive (ALK+) non-small cell lung cancer (NSCLC) from a Canadian healthcare perspective. Methods: A partitioned survival model with three health states (progression-free, progressive, and death) was developed to compare ceritinib versus other alternatives in patients with ALK+ NSCLC who were previously treated with an ALK inhibitor. Comparators were chosen based on reported utilization from a retrospective Canadian chart study; comparators were pemetrexed, best-supportive care (BSC) and historical control. Progression-free survival and overall survival for ceritinib were estimated using data from reported single-arm clinical trials (ASCEND-1(NCT01283516) and ASCEND-2(NCT01685060)). Survival data for comparators were obtained from published clinical trials in general NSCLC population and from a Canadian retrospective chart study in ALK+ patients treated with crizotinib. Parametric models were used to extrapolate outcomes beyond trial period. Drug acquisition, administration, resource use and adverse event (AE) costs were obtained from public databases. Utilities for health states and disutilities for AEs based on EQ-5D were derived from literature. Incremental costs per quality-adjusted life year (QALY) gained were estimated. Univariate and probabilistic sensitivity analyses were performed. Results: Over 4 years, ceritinib was associated with 0.86 QALYs and total direct costs of $89,740 for post-ALK population. The incremental cost per QALY was $149,117 comparing ceritinib vs. BSC, $80,100 vs. pemetrexed, and 104,436 vs. historical controls. Additional scenarios included comparison to docetaxel with an ICER/QALY of $149,780 and utility scores reported from PROFILE 1007, with a reported ICER/QALY ranging from $62,543 vs. pemetrexed to $119,735 vs. BSC. Sensitivity
